PPARGC1A and diabetic kidney disease: Additionally, rosiglitazone could induce the expression of PGC-1α, finally exhibiting protective effects against oxidative stress, glomerulosclerosis, and tubulointerstitial fibrosis in an experimental model of DKD [275].